Grant Sweep

Consolidated research funding across disease areas and research fields — federal, foundation, state & industry sources in one filterable place.

← Back to opportunities
OpenR61Clinical trial: Not allowed

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

National Institutes of Health (NIH) · NIH Institute/Center · PAR-25-059

Source: Grants.gov · View original posting ↗

Award
Up to $750K
Deadline
Oct 20, 2027
Letter of intent
Mechanism
R61
Duration
Expected awards
Funding cycle
Standard NIH dates
Open date
Oct 22, 2024
Total funding
$750K total
Clinical trial
Not allowed
Small businessGovernmentHigher educationNonprofitForeign entities

Research areas

Biomarkers & diagnosticsTherapeutics & drug discovery

Auto-classified from the title and description (keyword-based) — may be imperfect.

Description

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological or neuromuscular disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network (BPN) or other translational programs.

Data notes: administering NIH institute could not be identified from the opportunity number.